HOLZKIRCHEN, Germany, Feb. 13, 2018 /PRNewswire/ — Sandoz, a Novartis division, today announced the US FDA approval and launch of Glatopa® (glatiramer acetate injection) 40 mg/mL.
Glatopa (glatiramer acetate injection) 40 mg/mL is FDA-approved as a fully-substitutable, AP-rated…

Source: https://www.prnewswire.com/news-releases/sandoz-announces-us-fda-approval-and-launch-of-glatopa-40-mgml-three-times-a-week-generic-option-for-relapsing-forms-of-multiple-sclerosis-300597694.html

This entry was posted on Tuesday, February 13th, 2018 at 1:25 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.